Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company  is placed second among the best cancer stocks on our list.

TheFly reported on January 9 that Scotiabank analyst Louise Chen raised BMY’s price target to $60 from $53 while maintaining a Sector Perform rating. According to the analyst, investors find the stock appealing because to its low valuation and a “catalyst-rich” 2026.

Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

Separately, on January 12, Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 SCOUT-HCM trial, which assessed Camzyos (mavacamten) in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), yielded positive topline results. With a safety profile comparable to that of adults, the study, the first Phase 3 evaluation of a cardiac myosin inhibitor in patients with oHCM aged 12 to <18, fulfilled its primary and many secondary endpoints.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical leader in oncology, advancing innovative immuno-oncology and targeted therapies across solid tumors and hematologic malignancies, supported by a deep clinical pipeline and a strong legacy in cancer research and development.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.